Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
- Conditions
- Uterine LeiomyosarcomaRecurrent Uterine Sarcoma
- Interventions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00378911
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 674
- Registration Number
- NCT00375674
- Locations
- 🇨🇴
Instituto Nacional de Cancerologia - ESE, Bogota, Cundinamarca, Colombia
🇮🇪Beaumont Hospital, Dublin, Ireland
🇮🇱Assaf Harofeh Medical Center, Zerifin, Israel
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 488
- Registration Number
- NCT00373256
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 482
- Registration Number
- NCT00373113
- Locations
- 🇬🇧
Pfizer Investigational Site, Somerset, United Kingdom
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-12-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT00372424
- Locations
- 🇮🇹
Pfizer Investigational Site, Milano, Italy
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 69
- Registration Number
- NCT00372567
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00372775
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: sunitinib malateBiological: bevacizumabOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00357318
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00338884
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00329043
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.